Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Malignant Digestive System Neoplasm: early-phase trial registry
6 of 12 indexed Malignant Digestive System Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 6 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Malignant Digestive System Neoplasm: 12 US clinical trials tracked, 6 recruiting.
Malignant Digestive System Neoplasm is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 5 of these trials.
Enrollment posture brief
Registry condition malignant-digestive-system-neoplasm
OPEN 6 | RECR 50% | LATE 0 | EARLY 5 | RANK #1429 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Malignant Digestive System Neoplasm lists 6 open slots (50% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Malignant Digestive System Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Malignant Digestive System Neoplasm is recruiting above its size-band peers.
6 of 12 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Malignant Digestive System Neoplasm research.
M.D. Anderson Cancer Center accounts for 5 of 12 trials (41.7%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Malignant Digestive System Neoplasm enrolment sits around 90 participants.
Median target enrolment is 90 among the 12 trials that report a genuine target (sentinel values excluded). 7 of those (58.3%) plan for fewer than 100 participants.
-
Malignant Digestive System Neoplasm splits between interventional and observational designs.
8 interventional and 4 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
M.D. Anderson Cancer Center
NCT00991094
Molecular Epidemiology of Biliary Tree Cancers
M.D. Anderson Cancer Center
NCT05179486
Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study
Wake Forest University Health Sciences
NCT07215624
Evaluation of Portal Vein Stenting in Patients With Portal Vein Stenosis and Gastrointestinal Cancers
M.D. Anderson Cancer Center
NCT04629677
2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers
Emory University
NCT03800693
Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal or Gynecological Cancer
Mayo Clinic
NCT06855524
Perioperative Telemonitoring to Optimize Cancer Care and Outcomes
City of Hope Medical Center
NCT04986566
Massage Therapy in Reducing Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastrointestinal or Breast Malignancies
M.D. Anderson Cancer Center
NCT02221700
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
NCT02713269
GCC Agonist Signal in the Small Intestine
University of Wisconsin, Madison
NCT05107219
Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors
National Cancer Institute (NCI)
NCT02319018
Narrative Medicine for Improving Well-Being in Patients With Gastrointestinal Cancers
University of Southern California
NCT06374251
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Malignant Digestive System Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Malignant Digestive System Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Malignant Digestive System Neoplasm page
12 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Malignant Digestive System Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Malignant Digestive System Neoplasm trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Digestive System Neoplasm condition card totals 12 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.